BCL-2 Protein Frequency in Patients With High-Risk Diffuse Large B-Cell Lymphoma

Sao Paulo Medical Journal - Brazil
doi 10.1590/s1516-31802010000100004
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

FapUNIFESP (SciELO)

Related search

Combination of BCL-2 and MYC Protein Expression Improves High-Risk Stratification in Diffuse Large B-Cell Lymphoma

OncoTargets and Therapy
OncologyPharmacology
2015English

Plasma Immunoprofiling of Patients With High-Risk Diffuse Large B-Cell Lymphoma: A Nordic Lymphoma Group Study

Blood Cancer Journal
OncologyHematology
2016English

High-Risk Patients With Diffuse Large B-Cell Lymphoma Are Not Enrolled on Clinical Trials

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Young High Risk Patients With Diffuse Large B-Cell Lymphoma Including BCL-2/Myc Double Hit Lymphomas Benefit From Dose-Dense Immunochemotherapy With Early CNS Prophylaxis

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Frequent Expression of CD10 and BCL-6 in High-Grade Primary Extranodal Lymphoma With Diffuse Large B-Cell Lymphoma Morphology

Journal of clinical and experimental hematopathology : JCEH
Medicine
2004English

Diffuse Large B-Cell Lymphoma

2020English

Prognostic Value of Baseline FDG Pet Parameters in High Risk Diffuse Large B-Cell Lymphoma Patients

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

A New Subtype-Specific Monoclonal Antibody for IAP-survivin Identifies High-Risk Patients With Diffuse Large B-Cell Lymphoma and Improves the Prognostic Value of BCL-2

International Journal of Oncology
Cancer ResearchOncology
2008English

Blood Lymphocyte-To-Monocyte Ratio Identifies High-Risk Patients in Diffuse Large B-Cell Lymphoma Treated With R-Chop

PLoS ONE
Multidisciplinary
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy